Phase I study of cellular adoptive immunotherapy using genetically modified CD8+ HIV-specific T cells for HIV seropositive patients undergoing allogeneic bone marrow transplant. The Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Department of Medicine, Division of Oncology.
Riddell
S R
SR
Greenberg
P D
PD
Overell
R W
RW
Loughran
T P
TP
Gilbert
M J
MJ
Lupton
S D
SD
Agosti
J
J
Scheeler
S
S
Coombs
R W
RW
Corey
L
L
D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation; D016827:CD8 Antigens; D002985:Clinical Protocols; D003131:Combined Modality Therapy; D006679:HIV Seropositivity / Q000150:complications / Q000188:drug therapy / Q000628:therapy*; D006801:Humans; D016219:Immunotherapy, Adoptive; D016483:Lymphoma, AIDS-Related / Q000209:etiology / Q000601:surgery / Q000628:therapy*; D008875:Middle Aged; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology / Q000637:transplantation*; D015215:Zidovudine / Q000627:therapeutic use
D016827:CD8 Antigens; D015215:Zidovudine